Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion type Assertion NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_head.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion description "[In the current study, expression levels of let-7c, miR-30c, miR-141, and miR-375 in plasma from 59 prostate cancer (PC) patients with different clinicopathological characteristics and two groups of controls: 16 benign prostatic hyperplasia (BPH) samples and 11 young asymptomatic men (YAM) were analyzed to evaluate their diagnostic and prognostic value in comparison to prostate-specific antigen (PSA). miR-375 was significantly downregulated in 83.5% of patients compared to BPH controls and showed stronger diagnostic accuracy (area under the curve [AUC]=0.809, 95% CI: 0.697-0.922, p=0.00016) compared with PSA (AUC=0.710, 95% CI: 0.559-0.861, p=0.013).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_provenance.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion evidence source_evidence_literature NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_provenance.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion SIO_000772 25521481 NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_provenance.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion wasDerivedFrom befree-2016 NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_provenance.
- NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_assertion wasGeneratedBy ECO_0000203 NP1249201.RApE4P5FfYAC6LTAGNf7lfuaNQp-WUK_keXhfiJ2Yrj6A130_provenance.